<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712670</url>
  </required_header>
  <id_info>
    <org_study_id>Oral001</org_study_id>
    <nct_id>NCT03712670</nct_id>
  </id_info>
  <brief_title>Nutraceutical Support With Omega-3</brief_title>
  <official_title>Treatment of Exudative Age-Related Macular Degeneration With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Brescia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although evidence have clearly proved that intravitreal injection of vascular endothelial
      growth factor antagonists prevents vision loss and may even improve visual acuity in patients
      with neovascular AMD, a significant percentage of patients continue to lose visual acuity.
      Moreover, monthly intravitreal injections represent a burden for society as well as the
      caregiver.

      Combination therapy with either topical 0.1% pranoprofen or nutraceutical support with AREDS2
      formula plus omega-3 might act synergistically with intravitreal injection, offering valuable
      therapeutic support to aflibercept injections in patients requiring long-term treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">March 15, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central Retinal Thickness (microns)</measure>
    <time_frame>12-month</time_frame>
    <description>Optical Coherence Tomography will be used to assess central retinal thickness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity (LogMAR)</measure>
    <time_frame>12-month</time_frame>
    <description>ETDRS charts will be used to assess best corrected visual acuity</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Retinal Disease</condition>
  <arm_group>
    <arm_group_label>AM group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal aflibercept monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal aflibercept along with 0.1% pranoprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AN group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal aflibercept plus daily supplementation of nutraceutical tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>monthly intravitreal injections</description>
    <arm_group_label>AM group</arm_group_label>
    <arm_group_label>AN group</arm_group_label>
    <arm_group_label>AP group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pranoprofen</intervention_name>
    <description>0.1% pranoprofen 3 times a day topical eye drops administration</description>
    <arm_group_label>AP group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carotenoids</intervention_name>
    <description>daily supplementation of nutraceutical tablets containing the AREDS2 formulation</description>
    <arm_group_label>AN group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  provision of written informed consent and compliance with study assessments for the
             full duration of the study

          -  age &gt; 40 years

          -  presence of treatment-naïve neovascular AMD

        Exclusion Criteria:

          -  any previous intravitreal treatment

          -  previous laser treatment in the study eye

          -  myopia &gt; 7 diopters in the study eye

          -  concurrent eye disease in the study eye that could compromise visual acuity (e.g.,
             diabetic retinopathy and advanced glaucoma)

          -  concurrent corneal epithelial disruption or any condition that would affect the
             ability of the cornea to heal

          -  known sensitivity to any component of the formulations being investigated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>AREDS2 Research Group, Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBee W, Sperduto R, Ferris FL. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology. 2012 Nov;119(11):2282-9. doi: 10.1016/j.ophtha.2012.05.027. Epub 2012 Jul 26.</citation>
    <PMID>22840421</PMID>
  </reference>
  <reference>
    <citation>Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL 3rd, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Chandra SR, Blodi BA, Domalpally A, Friberg T, Wong WT, Rosenfeld PJ, Agrón E, Toth CA, Bernstein PS, Sperduto RD. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014 Feb;132(2):142-9. doi: 10.1001/jamaophthalmol.2013.7376.</citation>
    <PMID>24310343</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Brescia</investigator_affiliation>
    <investigator_full_name>Francesco Semeraro</investigator_full_name>
    <investigator_title>Dr. Francesco Semeraro</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyranoprofen</mesh_term>
    <mesh_term>Carotenoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

